1. Home
  2. RUBI vs CMND Comparison

RUBI vs CMND Comparison

Compare RUBI & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RUBI

Rubico Inc.

N/A

Current Price

$0.86

Market Cap

3.1M

ML Signal

N/A

Logo Clearmind Medicine Inc.

CMND

Clearmind Medicine Inc.

HOLD

Current Price

$2.58

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUBI
CMND
Founded
N/A
2017
Country
Marshall Islands
Canada
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1M
2.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RUBI
CMND
Price
$0.86
$2.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
797.2K
138.0K
Earning Date
05-06-2020
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,139,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$1.74
52 Week High
$200.70
$61.60

Technical Indicators

Market Signals
Indicator
RUBI
CMND
Relative Strength Index (RSI) N/A 60.76
Support Level N/A $2.12
Resistance Level N/A $2.69
Average True Range (ATR) 0.00 0.29
MACD 0.00 -0.04
Stochastic Oscillator 0.00 81.00

Price Performance

Historical Comparison
RUBI
CMND

About RUBI Rubico Inc.

Rubico Inc operates as a holding company. It is an eco-conscious international crude oil shipping company. The company's primary business is the ownership and operation of an eco-conscious fleet of tanker vessels designed for enhanced fuel efficiency, reduced greenhouse emissions, and a wide range of environmentally friendly technologies.

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Share on Social Networks: